Fiona Hilton

707 total citations
13 papers, 526 citations indexed

About

Fiona Hilton is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Fiona Hilton has authored 13 papers receiving a total of 526 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Immunology. Recurrent topics in Fiona Hilton's work include HER2/EGFR in Cancer Research (6 papers), Biosimilars and Bioanalytical Methods (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Fiona Hilton is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Biosimilars and Bioanalytical Methods (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Fiona Hilton collaborates with scholars based in United States, Ukraine and Japan. Fiona Hilton's co-authors include Eric Rubinstein, Claudio Viscoli, John Rex, Markus Ruhnke, Richat Abbas, Magdolna Dank, Riccardo Masetti, Ira Jacobs, Philip E. Lammers and Vladimir Vladimirov and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Fiona Hilton

13 papers receiving 513 citations

Peers

Countries citing papers authored by Fiona Hilton

Since Specialization

Citations

This map shows the geographic impact of Fiona Hilton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fiona Hilton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fiona Hilton more than expected).

Fields of papers citing papers by Fiona Hilton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fiona Hilton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fiona Hilton. The network helps show where Fiona Hilton may publish in the future.

Co-authorship network of co-authors of Fiona Hilton

This figure shows the co-authorship network connecting the top 25 collaborators of Fiona Hilton. A scholar is included among the top collaborators of Fiona Hilton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fiona Hilton. Fiona Hilton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	The relationship between weight gain during chemotherapy and outcomes in patients with advanced non‐small cell lung cancer 2024 ·Journal of Cachexia Sarcopenia and Muscle ·Eric Roeland, Florian J. Fintelmann, Fiona Hilton, Ruoyong Yang, Ed Whalen, Lisa Tarasenko, Roberto A. Calle, Philip Bonomi	1
2	Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study 2022 ·BioDrugs ·Rubi K. Li, Eriko Tokunaga, Hryhoriy Adamchuk, Vladimir Vladimirov, Eduardo Yáñez, Keun Seok Lee, Igor Bondarenko, (unknown), Fiona Hilton, Tomofumi Ishikawa, (unknown), Oleg Lipatov	12
3	Evaluation of weight gain and overall survival of patients with advanced non–small cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy. 2022 ·Journal of Clinical Oncology ·Eric Roeland, Florian J. Fintelmann, Fiona Hilton, Lisa Tarasenko, Roberto A. Calle, Philip Bonomi	2
4	Abstract P1-18-08: Trazimera (a trastuzumab biosimilar) in HER2-positive metastatic breast cancer: Long-term safety and overall survival data 2020 ·Cancer Research ·Rubi K. Li, Oleg Lipatov, Hryhoriy Adamchuk, Vladimir Vladimirov, Eduardo Yáñez, (unknown), Amy Freyman, Fiona Hilton, Alexandra Thiele, (unknown)	2
5	PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study 2019 ·BioDrugs ·Niels Reinmuth, Maciej Bryl, Igor Bondarenko, Kostas Syrigos, Vladimir Vladimirov, (unknown), Angel H. Bair, Fiona Hilton, Katherine Liau, Kazuo Kasahara	38
6	Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer 2018 ·British Journal of Cancer ·Philip E. Lammers, Magdolna Dank, Riccardo Masetti, Richat Abbas, Fiona Hilton, (unknown), Ira Jacobs	46
7	A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer. 2018 ·Journal of Clinical Oncology ·Mark A. Socinski, Joachim von Pawel, Kazuo Kasahara, Igor Bondarenko, Konstantinos Syrigos, Vladimir Vladimirov, Maciej Bryl, (unknown), (unknown), Fiona Hilton, Katherine Liau, Roy S. Herbst	2
8	An Adjustable Dalteparin Sodium Dose Regimen for the Prevention of Clotting in the Extracorporeal Circuit in Hemodialysis: A Clinical Trial of Safety and Efficacy (the PARROT Study) 2018 ·Canadian Journal of Kidney Health and Disease ·Steven Soroka, Mohsen Agharazii, Sandra Donnelly, Louise Roy, Norman Muirhead, Serge Cournoyer, Martin MacKinnon, Neesh Pannu, Brendan J. Barrett, François Madore, Karthik Tennankore, Jo‐Anne Wilson, Fiona Hilton, Nancy Sherman, Kevin D. Wolter, John Orazem, (unknown)	5
9	A randomized, double-blind study of PF-05280014 (a potential trastuzumab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for HER2-positive metastatic breast cancer 2017 ·Annals of Oncology ·Mark D. Pegram, Elizabeth Tan-Chiu, Amy Freyman, (unknown), Fiona Hilton, Charles Zacharchuk, Reginald B. Ewesuedo	13
10	A randomized, double-blind study of PF-05280014 (a potential biosimilar) vs trastuzumab, both given with docetaxel (D) and carboplatin (C), as neoadjuvant treatment for operable human epidermal growth factor receptor 2-positive (HER2+) breast cancer 2017 ·Annals of Oncology ·Philip E. Lammers, Magdolna Dank, Riccardo Masetti, Richat Abbas, Fiona Hilton, (unknown), (unknown)	6
11	The role of training in effective simulated self-injection of subcutaneous depot medroxyprogesterone acetate: observations from a usability study 2016 ·Contraception ·Irina V Kaplan, Douglas S. Ross, Fiona Hilton, (unknown), Kevin D. Wolter	6
12	Abstract OT3-1-02: A Phase 3 randomized, double-blind trial comparing PF-05280014 + docetaxel and carboplatin vs. trastuzumab + docetaxel and carboplatin for neoadjuvant treatment of operable HER2+ breast cancer 2015 ·Cancer Research ·Ira Jacobs, (unknown), Fiona Hilton, John Orazem, Richat Abbas, Charles Zacharchuk	3
13	Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial 2005 ·The Lancet ·(unknown), (unknown), Markus Ruhnke, (unknown), Claudio Viscoli, John Rex, (unknown), Eric Rubinstein, (unknown), (unknown), (unknown), (unknown), Fiona Hilton, (unknown)	390

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact